A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance

Cancer

Volumn 78, Issue 11, 1996, Pages 2427-2436

  Minderman, Hans ^a,f   Vanhoefer, Udo ^b   Toth, Karoly ^a   Minderman, M Denice ^a   Rustum, Youcef M ^a   Scheper, R J ^c   Slovak, M L ^d   Greco, W R ^e   Parsons, J C ^e   Baer, M R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e Biomathematics Department

^f ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

CD34; LRP; MRP; multidrug resistance; P glycoprotein; topoisomerase II

Indexed keywords

AMSACRINE; CD34 ANTIGEN; DAUNORUBICIN; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; IDARUBICIN; RNA; VINCRISTINE; VON WILLEBRAND FACTOR;

ARTICLE; CARCINOMA CELL; CLONING; CONTROLLED STUDY; CROSS RESISTANCE; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD34; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 10544248586     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961201)78:11<2427::AID-CNCR22>3.0.CO;2-1     Document Type: Article

References (48)

1. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984;133(1):157-65.
2. Civin C. Human mono-myeloid cell membrane antigens. Exp Hematol 1990;18:461-76.
3. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
4. Carlo-Stella C, Mangoni L, Almici C, Frassoni F, Fiers W, Rizoli V. Growth of CD34+ acute myeloblastic leukemia colony-forming cells in response to recombinant growth factors. Leukemia 1990;4:561-6.
5. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990;75:2417-26.
6. Traweek ST, Kandalaft PL, Mehta P, Battifora H. The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 1991;96:25-31.
7. Aiba S, Tabata N, Ishii H, Ootani H, Tagami H. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34. Br J Dermatol 1992;127:79-84.
8. He X-Y, Antao VP, Basila D, Marx JC, Davis BR. Isolation and molecular characterization of the human CD34 gene. Blood 1992;79(9):2296-302.
9. Simmons DL, Satterthwaite AB, Tenen DG, Seed B. Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells. J Immunol 1992;148(1):267-71.
10. Nakamura Y, Komano H, Nakauchi H. Two alternative forms of cDNA encoding CD34. Exp Hematol 1993;21:236-42.
11. Krause DS, Fackler MJ, Smith OM, May WS. Two forms of CD34 protein are expressed in human KMT2 and KG1a cells. Proceedings 35th Annual Meeting of the American Society of Hematology 1993:110a.
12. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94.
13. Mason J, Bessert E, Mullen M, Shea T. P-glycoprotein expression on mobilized peripheral blood progenitor cells correlates with CD34. Proc Am Assoc Cancer Res 1992;33:199.
14. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992;79(2):473-6.
15. Baer MR, Minderman H, Frankel SR, Herzig GP, Rustum Y, Stewart CC, et al. High frequency of CD34 and MDR1 expression in acute myeloid leukemia evolved from antecedent bone marrow disorders. Proc Am Soc Clin Oncol 1993; (12):315.
16. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152.
17. Endicott JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 1989;58:137.
18. Willman CL, Kopecky KJ, Appelbaum F, Grever MR, Head DR, Elias L, et al. Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML):CD34, but not multidrug resistance (MDR) gene expression is associated with a decreased complete remission (CR) rate and CD34-positive patients more frequently achieve CR with high-dose cytosine arabinoside. Proc Am Soc Clin Oncol 1992;11:262.
19. Jamali MAA, Yin M-B, Mazzoni A, Bankusli I, Rustum YM. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933. Cancer Chemother Pharmacol 1989;25:77-83.
20. Soule HD, Vasquez J, Long A, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409-16.
21. Fairchild CR, Ivy SP, Kao-shan C-S, Whang-Peng J, Rosen N, Israel MA, et al. Isolation of amplified and overexpression DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 1987;47:5141-8.
22. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 1985;11:117-26.
23. Bhalla K, Hindenburg A, Taub RN, Grant S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res 1985;45:3657-62.
24. Marsh W, Sicheri R, Center MS. Isolation and characterization of adriamycin-resistant HL60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res 1986;46:4053-7.
25. McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL, Center MS. Mechanisms of multidrug resistance in HL60 cells: analysis of resistance associated membrane proteins and levels of MDR gene expression. Biochem Pharmacol 1989;38:3611-9.
26. McGrath T, Center MS. Adriamycin resistance in HL60 cells in the abscence of detectable P-glycoprotein. Biochem Biophys Res Commun 1987;145:1171-6.
27. Marsh W, Center MS. Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells. Cancer Res 1987;47:5080-6.
28. Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two tumor cell lines. Cancer Res 1988;48:2793-7.
29. Greco WR, Park HS, Rustum YM. An application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatnum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1990;50:5318-27.
30. Toth K, Vaughan MM, Slocum HK, Arredondo MA, Takita H, Baker RM, et al. New immunohistochemical "sandwich" staining method for mdr1 P-Glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am J Pathol 1994;144(2):227-36.
31. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen HM, et al. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993;53:1475-80.
32. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJLM, Scheper RJ, et al. Immunochemical detection of the multi-drug resistance-associated protein MRP in human multi-drug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994;54:4557-64.
33. Andrews RG, Singer JW, Bernstein ID. Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 1986;67:842-5.
34. Habig WH, Pabst MJ, Jakoby WB. Glutathione s-transferase. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974;249:7130-9.
35. Günzler WA, Kremers H, Flohe L. An improved coupled test procedure for glutathione peroxidase (EC 1.11.1.9) in blood. Z Klin Chem Klin Biochem 1974;12:444-8.
36. Smith IK, Vierheller TL, Thorne CA. Assays of glutathione reductase in crude tissue homogenates using 5,5′-dithiobis (2-nitrobenzoic acid). Anal Biochem 1988;175:408-13.
37. Deutsch J. Glucose-6-phosphate dehydrogenase. In: Bergmeyer UB, Bergmeyer J, Grassl M, editors. Methods of enzymatic analysis. 3rd edition. Deerfield Beach, FL: Verlag Chemie, 1983:190-7.
38. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
39. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 7q21-22. Proc Natl Acad Sci USA 1988;85:7177-81.
40. Harker WG, Slade DL, Pan RL, Feldhoff PW, Sullivan DM, Holguin MH. Alterations in the topoisomerase-alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase-beta enzyme in a mitoxantrone-resistant HL60 human leukemia cell line. Cancer Res 1995;55:1707-16.
41. Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A, et al. Surface marker expression in adult acute myeloid leukemia:correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989; 72:161-6.
42. Borowitz MJ, Gockerman JP, Moore JO, Civin CI, Page SA, Robertson J, et al. Clinicopathologic and cytogeneticfeatures of CD34 (MY10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol 1989;91:265-70.
43. Geller RB, Zahurak M, Hurwitz CA, Burcke PJ, Karp JE, Piantadosi S, et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukemia: the significance of the stem-cell glycoprotein CD34 (MY-10). Br J Haematol 1990;76:340-7.
44. Baumhueter S, Singer MS, Henzel W, Hemmerich S, Renz M, Rosed SD, et al. Binding of L-selectin to the vascular sialomucin CD34. Science 1993;262:436-8.
45. O'Kane Murphy B, Jackson JD, Bociek G, Costas P, Korth D, Kuszynski C, et al. CD34 analysis of GM-CSF mobilized peripheral blood stem cells. Blood 1993;82(10):488a.
46. Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, et al. Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 1991;63:237-41.
47. Baer MR, Augustinos P, Kinniburgh AJ. Defective c-myc and c-myb RNA turnover in acute myeloid leukemia cells. Blood 1992;79(5):1319-26.
48. Kastan MB, Stone KD, Civin C. Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood 1989;74:1517-24.